Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy.
about
A combined oral contraceptive containing 30 mcg ethinyl estradiol and 3.0 mg drospirenone does not impair endothelium-dependent vasodilation.Ethinyl estradiol-to-desogestrel ratio impacts endothelial function in young womenState of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS).Estrogen-free oral hormonal contraception: benefits of the progestin-only pill.Development of a mouse model of menopausal ovarian cancer.
P2860
Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Preclinical profiles of proges ...... d hormone replacement therapy.
@ast
Preclinical profiles of proges ...... d hormone replacement therapy.
@en
Preclinical profiles of proges ...... d hormone replacement therapy.
@nl
type
label
Preclinical profiles of proges ...... d hormone replacement therapy.
@ast
Preclinical profiles of proges ...... d hormone replacement therapy.
@en
Preclinical profiles of proges ...... d hormone replacement therapy.
@nl
prefLabel
Preclinical profiles of proges ...... d hormone replacement therapy.
@ast
Preclinical profiles of proges ...... d hormone replacement therapy.
@en
Preclinical profiles of proges ...... d hormone replacement therapy.
@nl
P356
P1476
Preclinical profiles of proges ...... nd hormone replacement therapy
@en
P2093
P304
P356
10.1067/MOB.2001.117415
P407
P433
P577
2001-08-01T00:00:00Z